ReCode Therapeutics nabs $80m Series A

ReCode Therapeutics, a provider of precision medicines for pulmonary diseases, has raised $80 million in Series A financing.

26 March 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles